The acute respiratory distress syndrome (ards) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Acute Respiratory Distress Syndrome (ARDS) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.
The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.
Order your report now for swift delivery @
Scope Of Acute Respiratory Distress Syndrome (ARDS) Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Acute Respiratory Distress Syndrome (ARDS) Market Overview
Market Drivers –
The growing prevalence of pneumonia is expected to propel the growth of the acute respiratory distress syndrome (ARDS) market going forward. Pneumonia is an infection that affects one or both lungs, causing the lungs’ air sacs, or alveoli, to fill up with fluid or pus. Pneumonia causes an inflammatory reaction in the lungs, increasing blood vessel permeability and fluid leakage into the alveoli. This fluid buildup interferes with the exchange of oxygen and carbon dioxide, causing respiratory discomfort. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, the number of deaths due to pneumonia in the United States was 41,309, with a mortality rate of 12.4 deaths per 100,000 population. Therefore, the growing prevalence of pneumonia drives the growth of the acute respiratory distress syndrome (ARDS) market.
Market Trends –
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative drugs and supplements, such as Aviptadil, HSP90 inhibitors and others to sustain their position in the market. Aviptadil is a synthesized vasoactive intestinal peptide (VIP) that binds specifically to receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Aviptadil to treat acute respiratory distress syndrome. Aviptadil, a vasoactive intestinal peptide supplement, improves breathing and lowers mortality in ARDS patients. This is accomplished through Aviptadil’s ability to protect and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis and suppress IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.
The acute respiratory distress syndrome (ards) market covered in this report is segmented –
1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
Get an inside scoop of the acute respiratory distress syndrome (ards) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
Regional Insights –
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2023. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.
Table of Contents
- Executive Summary
- Acute Respiratory Distress Syndrome (ARDS) Market Report Structure
- Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
- Acute Respiratory Distress Syndrome (ARDS) Market – Macro Economic Scenario
- Acute Respiratory Distress Syndrome (ARDS) Market Size And Growth
…..
- Acute Respiratory Distress Syndrome (ARDS) Market Competitor Landscape And Company Profiles
- Key Mergers And Acquisitions
- Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
